The Top 5 Biosimilars Articles for the Week of April 6

The Center for Biosimilars® recaps the top stories for the week of April 6, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 6, 2020.

Number 5: As the coronavirus disease (COVID-19) pandemic spreads, it will continue to affect the biopharmaceutical industry. Biosimilars are no exception, and the effect on their uptake and adoption will be multifaceted, according to ZS.

Number 4: Following close on the heels of its US approval for biosimilar rituximab, Pfizer has gained the European Commission’s nod and aims to launch in coming months.

Number 3: Self-insured companies could have saved between $407 million and $1.4 billion in 2018 had they switched completely from reference biologics, infliximab and filgrastim, to biosimilars, according to a report.

Number 2: Amid the coronavirus pandemic, the FDA issued guidance stressing the importance that manufacturers notify it of discontinuations and manufacturing interruptions so that the agency can implement contingency measures.

Number 1: The race to find a way to knock down the coronavirus pandemic has attracted companies with stakes in the biosimilar game. The winner could take all.

To read all of these articles and more, visit